Urological Research

, Volume 24, Issue 4, pp 239–244 | Cite as

The 9p21 region in bladder cancer cell lines: large homozygous deletions inactivate the CDKN2, CDKN2B and MTAP genes

  • W. M. Stadler
  • O. I. Olopade
Original Paper

Abstract

Homozygous and hemizygous deletions of 9p21 are the earliest and most common genetic alteration in bladder cancer. The identification of two cell cycle regulators, CDKN2 and CDKN2B, that map to the common region of deletion has prompted the hypothesis that they are critical tumor suppressor genes in this malignancy. However, controversy as to whether these genes are the only or even the most important target in bladder cancer oncogenesis remains. To more clearly determine the effect of these 9p21 alterations, we mapped the homozygous deletions and performed a detailed mutational and expression analysis for CDKN2, CDKN2B and a closely linked gene, methylthioadenoside phosphorylase (MTAP), in 16 established bladder cancer cell lines. Nine of the 16 lines exhibit large (30 to >2000 kb) homozygous deletions on 9p21. All deletions include at least one exon of CDKN2, eight of nine include CDKN2B, and six of nine include MTAP. MTAP function correlates with the genomic deletions. SSCP and sequence analysis does not reveal any inactivating point mutations of CDKN2 or of CDKN2B in any of the cell lines without homozygous deletions, and all express the CDKN2 and the CDKN2B mRNA as well as the encoded p16 protein. The p16 protein levels vary widely and are correlated with absent pRb expression. We conclude that the 9p21 deletions in bladder cancer usually inactivate the CDKN2, CDKN2B, and MTAP genes but that CDKN2 is the most common target. Other mechanisms for inactivating this gene in bladder cancer appear to be uncommon.

Key words

Cell cycle inhibitors p16 p15 MTS MTS2 INK4 INK4b 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cairns P, Tokino K, Eby Y, Sidranksy D (1994a) Homozygous deletion of 9p21 in primary human bladder tumors detected by competitive multiplex polymerase chain reaction. Cancer Res 54:1422Google Scholar
  2. 2.
    Cairns P, Mao L, Merlo A, Lee DJ, Eby Y, Tokino K, Riet P, Blaugrund JE, Sidransky D (1994b) Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science (Washington DC) 265:415Google Scholar
  3. 3.
    Cairns P, Polascik TJ, Eby Y, Tokino K, Colifano J et al (1995) Frequency of homozygous deletions at p16/CDKN2 in primary human tumors. Nature Gen 11:210Google Scholar
  4. 4.
    Cheng JQ, Jhanwar SC, Lu YY, Testa JR (1993) Homozygous deletions within 9p21-22 identify a small critical region of chromosomal loss in human malignant mesotheliomas. Cancer Res 53:4761Google Scholar
  5. 5.
    Dreyling MH, Bohlander SK, Adeyanju MO, Olopade OI (1995) Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization. Cancer Res 55:984Google Scholar
  6. 6.
    Fountain JW, Karayiorgou M, Ernstoff MS et al (1992) Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA 89:10557Google Scholar
  7. 7.
    Gonzalez-Zuleta M, Shibata A, Ohneseit PF, Spruck CH, Busik C, Shaman M, Elboz M, Nichols PW, Gonzalgo ML, Malmström P-U, Jones PA (1995) Frequent alterations of the p16INK4 locus in squamous cell carcinoma distinguish it from transitional cell carcinoma of the bladder. J Natl Cancer Inst 87:1383Google Scholar
  8. 8.
    Goodrich DW, Chen Y, Scully P, Lee W-H (1992) Expression of the retinoblastoma gene product in bladder carcinoma cells associates with a low frequency of tumor formation. Cancer Res 52:1968Google Scholar
  9. 9.
    Hannon GJ, Beach D (1994) p15INK4b is a potential effector of TGF-β-induced cell cycle arrest. Nature 371:257Google Scholar
  10. 10.
    Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigain SV, Stockert E, Day RS, Johnson BE, Skolnick MH (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC) 264:436Google Scholar
  11. 11.
    Knudson AG (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:1631Google Scholar
  12. 12.
    Kwiatkowski K, Diaz M (1992) A dinucleotide repeat in the human IFNA locus. Human Mol Gen 1:658Google Scholar
  13. 13.
    Liu Q, Neuhausen S, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, Eddington K, Allalunis-Turner MJ, Skolnick MH, Fujimara FK, Kamb A (1995) CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene 10:1061Google Scholar
  14. 14.
    Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D (1995) A novel p16INK4A transcript. Cancer Res 55:2995Google Scholar
  15. 15.
    Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Siransky D (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med 1:686Google Scholar
  16. 16.
    Miyao N, Tsai YL, Lerner SP, et al (1993) Role of chromosome 9 in human bladder cancer. Cancer Res 53:4066Google Scholar
  17. 17.
    Mosman T (1983) Rapid colorimetric assay for cellular growth and survival. Application to proliferation and cytotoxicity assays. J Immunol Meth 65:55Google Scholar
  18. 18.
    Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (London) 368:753Google Scholar
  19. 19.
    Olopade OI, Buchhagen DL, Malik K et al (1993) Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res 53:2410Google Scholar
  20. 20.
    Olopade OI, Pomykala HM, Hagos F, Sveen LW, Espinosa R III, Dreyling MH, Gursky S, Stadler WM, LeBeau MM, Bohlander SK (1995) Construction of a 2.8 megabase YAC contig and cloning of the methylthioadenosine phosphorylase (MTAP) gene from the tumor suppressor locus on 9p21. Proc Natl Acad Sci USA 92:6489Google Scholar
  21. 21.
    Perucca D, Szepetowske P, Simon M-P, Gaudray P (1990) Molecular genetics of human bladder carcinomas. Cancer Genet Cytogenet 49:143Google Scholar
  22. 22.
    Porterfield BW, Pomykala H, Maltepe E, Bohlander SK, Rowley JD, Diaz MO (1993) The use of methylthioadenosine phosphorylase activity to select for human chromosome 9 in interspecies and intraspecies hybrid cells. Som Cell Mol Gen 19:469Google Scholar
  23. 23.
    Ruppert JM, Tokino K, Sidransky D (1993) Evidence for two bladder cancer suppressor loci on human chromosome 9. Cancer Res 53:5093Google Scholar
  24. 24.
    Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704Google Scholar
  25. 25.
    Spruck CH III, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzales F, Tsai YC, Jones PA (1994) p16 gene in uncultured tumors. Nature (London) 370:183Google Scholar
  26. 26.
    Stadler WM, Sherman J, Bohlander SK, Roulston D, Dreyling M, Rukstalis D, Olopade OI (1994) Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer. Cancer Res 54:2060Google Scholar
  27. 27.
    Tarmin L, Yin J, Zhou X, Suzuki H, Jiang H-Y et al (1994) Frequent loss of heterozygosity on chromosome 9 in adenocarcinoma and squamous cell carcinoma of the oesophagus. Cancer Res 54:6094Google Scholar
  28. 28.
    Van der Riet P, Nawroz H, Hruban RH, Corio R, Tokino K, Koch W, Sidransky D (1994) Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 54:1156Google Scholar
  29. 29.
    Weissenbach J, Gyapay G, Dib C, Vignal A, Morissette J, Millasseau P, Vaysseix G, Lathrop M (1992) A second-generation linkage map of the human genome. Nature (London) 359:794Google Scholar
  30. 30.
    Yeager T, Stadler W, Belair C, Puthenveettil J, Olopade O, Reznikoff C (1995) Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res 55:493Google Scholar
  31. 31.
    Xu L, Sgroi D, Sterner CJ, Beauchamp RL, Pinney DM, Keel S, Ueki K, Rutter JL, Buckler AJ, Louis DN, Gusella JF, Ramesh V (1994) Mutational analysis of CDKN2 (MTS1/p16INK4) in human breast carcinomas. Cancer Res 54:5262Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • W. M. Stadler
    • 1
  • O. I. Olopade
    • 1
  1. 1.Department of Medicine, Section of Hematology/OncologyUniversity of ChicagoChicagoUSA

Personalised recommendations